{"nctId":"NCT01182376","briefTitle":"SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI","startDateStruct":{"date":"2010-11"},"conditions":["Atrial Fibrillation"],"count":33,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Multaq® (dronedarone)","type":"EXPERIMENTAL","interventionNames":["Drug: dronedarone"]}],"interventions":[{"name":"dronedarone","otherNames":["Multaq®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients age 18 and older\n* Must carry a diagnosis of Paroxysmal Atrial Fibrillation for 1 months or longer prior to being enrolled.\n* AAD: Multaq® (dronedarone) candidate\n* Patients have given informed consent\n\nExclusion Criteria:\n\n* Patients who are unavailable to continue follow-up at the University of Utah outpatient clinic.\n* Patients weighing \\>200 lbs (MR image efficacy decreases due to density)\n* Prior RF Ablation treatment for atrial fibrillation\n* Severe renal failure manifested by a chronic GFR of \\< 30 mL/min, or acute renal failure regardless of the GFR, until the renal function has stabilized. (Gadolinium contraindication)\n* Enrollment in any other investigational trial for anti-arrhythmic therapy\n* Any health related Gadolinium/MRI contraindications: Pacemaker devices, etc.\n* Pregnant women\n* Individuals with cognitive impairments who are unable to give informed consent\n* Multaq® (dronedarone) contraindications:\n\n  * NYHA Class IV heart failure or NYHA Class II - III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic\n  * Second- or third-degree atrioventricular (AV) block or sick sinus syndrome\n  * Bradycardia \\< 50 bpm\n  * Concomitant use of strong CYP 3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and ritonavir\n  * Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of Torsade de Pointes, such as phenothiazine anti-psychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics\n  * QTc Bazett interval ≥ 500 ms or PR interval \\> 280 ms\n  * Severe hepatic impairment\n  * Pregnant women\n  * Nursing mothers","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"LA Fibrosis","description":"The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":".07"},{"groupId":"OG001","value":"16.8","spread":".05"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["non compliance","other surgeries","Nausea","arrhythmias","drug interactions"]}}}